MetaCap

Bio-Rad Laboratories (BIO) vs 10x Genomics (TXG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

10x Genomics (TXG) has outperformed Bio-Rad Laboratories (BIO) over the past year, gaining 182.4% versus a gain of 13.3%. Over five years, BIO leads with a -52.2% price change compared with -65.2% for TXG. Bio-Rad Laboratories is the larger company by market cap ($9.65 billion vs $6.81 billion), about 1.4 times the size, while 10x Genomics is growing revenue faster (+5.2% vs +0.7%).

On valuation, Bio-Rad Laboratories trades at a lower forward P/E (36.2x vs 597.7x for 10x Genomics). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -6.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIO+13.32%TXG+182.44%
+456%+205%-47%
Nov 21, 20251 yearNov 20, 2026
BIO-53.79%TXG-65.46%
+5%-48%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIO versus TXG key metrics
MetricBIOTXG
Share price$358.90$51.80
Market cap$9.65B$6.81B
1-day change-2.34%-9.72%
YTD return+18.45%+217.60%
1-year return+13.32%+182.44%
5-year return-52.16%-65.20%
P/E ratio (TTM)9.54—
Forward P/E36.23597.67
EPS (TTM)$37.64$-0.52
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.58B$642.82M
Revenue growth (YoY)+0.65%+5.25%
Net income (latest FY)$759.90M$-43.54M
Gross margin51.87%69.05%
Operating margin1.83%-9.49%
Net margin29.42%-6.77%
52-week high$396.23$102.81
52-week low$236.73$15.18
Distance from 52-week high-9.42%-49.62%
Analyst consensusholdbuy
Avg. price target upside-0.62%+31.54%
Average volume257.70K3.36M
Shares outstanding21.83M121.46M
Employees7,4501,178
SectorIndustrialsIndustrials
IndustryBiotechnology: Laboratory Analytical InstrumentsBiotechnology: Laboratory Analytical Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXG has outperformed BIO by 169.1 percentage points over the past year.
  • Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -6.8 cents for 10x Genomics.

About Bio-Rad Laboratories

BIO stock →

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.

Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees

About 10x Genomics

TXG stock →

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific.

Industrials · Biotechnology: Laboratory Analytical Instruments · 1,178 employees

BIO vs TXG FAQ

Which is bigger, Bio-Rad Laboratories or 10x Genomics?

Bio-Rad Laboratories (BIO) is larger, with a market capitalization of $9.65B compared with $6.81B for 10x Genomics (TXG).

Which stock has performed better over the past year, BIO or TXG?

TXG returned +182.44% over the past 12 months, compared with +13.32% for BIO (price return, excluding dividends). Past performance does not predict future results.

Are Bio-Rad Laboratories and 10x Genomics in the same industry?

Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.

More comparisons